{
    "clinical_study": {
        "@rank": "97450", 
        "arm_group": [
            {
                "arm_group_label": "Acetyl-L-carnitine", 
                "arm_group_type": "Active Comparator", 
                "description": "Acetyl-L-carnitine 2 gr tablets"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the effects of Acetyl-L-Carnitine, probiotics and antioxidant nutritional\n      substances administration on work productivity, daily activity, and fatigue in subjects with\n      chronic hepatitis C treated with Pegylated-Interferon-\u03b12b and Ribavirin."
        }, 
        "brief_title": "Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-\u03b12b Plus Ribavirin: Effect on Work Performance.", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Quality of Life", 
            "Daily Activity", 
            "Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": "Fatigue"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible patients are workers who are 18 years of age or older, infected by HCV with\n             a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS\n             AmpliPrep/COBAS TaqMan - ROCHE). HCV infected populations must have elevated serum\n             alanine transaminase levels and findings on liver biopsy consistent with chronic\n             infection. Cirrhotic patients have to have a Child-Pugh score less than 7 to be\n             eligible.\n\n        Exclusion Criteria:\n\n          -  Ineligible patients are those who had other liver diseases, as well as those who are\n             affected by cancer, severe jaundice, pulmonary and renal chronic diseases, prostatic\n             diseases, autoimmune diseases and diabetes mellitus. Excessive use of alcohol (>20\n             g/die) or hepato-toxic drugs. Other causes of exclusion include decompensated\n             cirrhosis, pregnancy, and contraindications for Peg-IFN-a or RBV therapy such as\n             cardiopathy, hemoglobinopathies, hemocromatosis, major depression or other severe\n             psychiatric pathological conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909557", 
            "org_study_id": "Unict10/1997"
        }, 
        "intervention": [
            {
                "arm_group_label": "Acetyl-L-carnitine", 
                "intervention_name": "Acetyl-L-carnitine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcarnitine", 
                "Carnitine", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acetyl-L-carnitine", 
            "Interferons", 
            "Ribavirin", 
            "Hepatitis C", 
            "Fatigue"
        ], 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Catania", 
                    "country": "Italy", 
                    "zip": "95125"
                }, 
                "name": "University of Catania, Cannizzaro Hospital"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Supplementation of Antioxidant Substances and Probiotics in HCV Correlated Liver Disease Treated With Interferon and Ribavirin. Studies on Biochemical and Virological Response and on Quality of Life.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Work performances", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909557"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Catania", 
            "investigator_full_name": "Mariano Malaguarnera", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Catania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Catania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}